Tumor-Associated Macrophages in Cancer Growth and Progression

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter reviews the key properties of tumor-associated macrophages (TAMs), emphasizing on the genetic evidence and the emerging targets for therapeutic intervention. TAMs derive from the circulating monocytes and are recruited at the tumor site by a tumor-derived chemotactic factor for monocytes. TAMs that have immunoregulatory and immunosuppressive activity produce growth factors that stimulate angiogenesis, remodel tissues, and facilitate invasion and metastasis. TAMs and the related immature myeloid suppressor cells have the properties of M2 macrophage populations that are supportive to tumors. In many human tumors, a high frequency of infiltrating TAMs is associated with poor prognosis. TAMs participate in the proangiogenic process by producing the angiogenic factor thymidine phosphorylase (TP), which promotes the endothelial cell migration in vitro and whose levels of expression are associated with tumor neovascularization. TAMs contribute to tumor progression also by producing proangiogenic and tumor-inducing chemokines, such as CCL2. Moreover, TAMs accumulate in the hypoxic regions of tumors, and hypoxia triggers a proangiogenic program in these cells.

Original languageEnglish
Title of host publicationCancer Immunotherapy
PublisherElsevier Inc.
Pages289-307
Number of pages19
ISBN (Print)9780123725516
DOIs
Publication statusPublished - 2007

Fingerprint

Macrophages
Tumors
Growth
Neoplasms
Monocytes
Thymidine Phosphorylase
Angiogenesis Inducing Agents
Chemotactic Factors
Myeloid Cells
Immunosuppressive Agents
Endothelial cells
Chemokines
Cell Movement

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tumor-Associated Macrophages in Cancer Growth and Progression. / Mantovani, Alberto; Allavena, Paola; Sica, Antonio.

Cancer Immunotherapy. Elsevier Inc., 2007. p. 289-307.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{713f5aae1ebc4fc6ba33bb07c31d213a,
title = "Tumor-Associated Macrophages in Cancer Growth and Progression",
abstract = "This chapter reviews the key properties of tumor-associated macrophages (TAMs), emphasizing on the genetic evidence and the emerging targets for therapeutic intervention. TAMs derive from the circulating monocytes and are recruited at the tumor site by a tumor-derived chemotactic factor for monocytes. TAMs that have immunoregulatory and immunosuppressive activity produce growth factors that stimulate angiogenesis, remodel tissues, and facilitate invasion and metastasis. TAMs and the related immature myeloid suppressor cells have the properties of M2 macrophage populations that are supportive to tumors. In many human tumors, a high frequency of infiltrating TAMs is associated with poor prognosis. TAMs participate in the proangiogenic process by producing the angiogenic factor thymidine phosphorylase (TP), which promotes the endothelial cell migration in vitro and whose levels of expression are associated with tumor neovascularization. TAMs contribute to tumor progression also by producing proangiogenic and tumor-inducing chemokines, such as CCL2. Moreover, TAMs accumulate in the hypoxic regions of tumors, and hypoxia triggers a proangiogenic program in these cells.",
author = "Alberto Mantovani and Paola Allavena and Antonio Sica",
year = "2007",
doi = "10.1016/B978-012372551-6/50080-8",
language = "English",
isbn = "9780123725516",
pages = "289--307",
booktitle = "Cancer Immunotherapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Tumor-Associated Macrophages in Cancer Growth and Progression

AU - Mantovani, Alberto

AU - Allavena, Paola

AU - Sica, Antonio

PY - 2007

Y1 - 2007

N2 - This chapter reviews the key properties of tumor-associated macrophages (TAMs), emphasizing on the genetic evidence and the emerging targets for therapeutic intervention. TAMs derive from the circulating monocytes and are recruited at the tumor site by a tumor-derived chemotactic factor for monocytes. TAMs that have immunoregulatory and immunosuppressive activity produce growth factors that stimulate angiogenesis, remodel tissues, and facilitate invasion and metastasis. TAMs and the related immature myeloid suppressor cells have the properties of M2 macrophage populations that are supportive to tumors. In many human tumors, a high frequency of infiltrating TAMs is associated with poor prognosis. TAMs participate in the proangiogenic process by producing the angiogenic factor thymidine phosphorylase (TP), which promotes the endothelial cell migration in vitro and whose levels of expression are associated with tumor neovascularization. TAMs contribute to tumor progression also by producing proangiogenic and tumor-inducing chemokines, such as CCL2. Moreover, TAMs accumulate in the hypoxic regions of tumors, and hypoxia triggers a proangiogenic program in these cells.

AB - This chapter reviews the key properties of tumor-associated macrophages (TAMs), emphasizing on the genetic evidence and the emerging targets for therapeutic intervention. TAMs derive from the circulating monocytes and are recruited at the tumor site by a tumor-derived chemotactic factor for monocytes. TAMs that have immunoregulatory and immunosuppressive activity produce growth factors that stimulate angiogenesis, remodel tissues, and facilitate invasion and metastasis. TAMs and the related immature myeloid suppressor cells have the properties of M2 macrophage populations that are supportive to tumors. In many human tumors, a high frequency of infiltrating TAMs is associated with poor prognosis. TAMs participate in the proangiogenic process by producing the angiogenic factor thymidine phosphorylase (TP), which promotes the endothelial cell migration in vitro and whose levels of expression are associated with tumor neovascularization. TAMs contribute to tumor progression also by producing proangiogenic and tumor-inducing chemokines, such as CCL2. Moreover, TAMs accumulate in the hypoxic regions of tumors, and hypoxia triggers a proangiogenic program in these cells.

UR - http://www.scopus.com/inward/record.url?scp=84882533487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882533487&partnerID=8YFLogxK

U2 - 10.1016/B978-012372551-6/50080-8

DO - 10.1016/B978-012372551-6/50080-8

M3 - Chapter

SN - 9780123725516

SP - 289

EP - 307

BT - Cancer Immunotherapy

PB - Elsevier Inc.

ER -